USPTO Releases Examiner Guidance for The Amgen Enablement Decision Attorney: Richard D. Kelly January 10, 2024 The USPTO today published its guidance to the examiners on the impact of the Amgen v....
USPTO Announces Revised Director Review Process July 26, 2023 On July 24, the USPTO announced a revised Director interim review process. Although the USPTO in July 2022 had requested comments on its ...
USPTO Releases Examiner Guidance for The Amgen Enablement Decision January 10, 2024 The USPTO today published its guidance to the examiners on the impact of the Amgen v. Sanofi,143 S. Ct. 1243 (2023)...
USPTO Issues Advance Notice of Proposed Rulemaking for America Invents Act (AIA) Proceedings Before the Patent Trial and Appeal Board April 20, 2023 The USPTO today announced Advance Notice of Proposed ...
Will Institution Rates Rise in Response to USPTO Initiatives? August 12, 2022 When it comes to IPR petitions filed in the Bio/Pharma space, USPTO data tells us that while Bio/Pharma petitions make ...
USPTO Decides an "Inventor" as a "Natural Person" April 28, 2020 The USPTO has published an apparently January 2020 Commissioner Decision effectively precluding the filing of patent applications where ...
USPTO Extends Cancer Immunotherapy Pilot Program October 24, 2022 To accelerate innovation in the health and medical fields, the USPTO published a Federal Register Notice announcing a fifth extension ...
USPTO: Proposed Changes to Terminal Disclaimer Practice in Joint Research Agreement Situations February 1, 2021 The USPTO proposes to modify the rules of practice when certain types of patent applicants ...
USPTO Announces Cancer Moonshot Expedited Examination Pilot Program December 9, 2022 Update by: Grace Kim and Alex Zhang The USPTO has published a Federal Register Notice announcing a new program:...
Show Me the Money – USPTO Fee Proposals Include Fee Provisions to Impact Applicant Behavior June 19, 2023 The USPTO has opened the discussion on its fees to be effective in 2025. While the PTO is ...